Reviewing Auris Medical (EARS) and Audentes Therapeutics (BOLD)

Auris Medical (NASDAQ: EARS) and Audentes Therapeutics (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Volatility and Risk

Auris Medical has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Audentes Therapeutics has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Auris Medical and Audentes Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auris Medical 0 0 2 0 3.00
Audentes Therapeutics 0 1 7 0 2.88

Auris Medical currently has a consensus target price of $4.50, indicating a potential upside of 1,074.93%. Audentes Therapeutics has a consensus target price of $36.71, indicating a potential downside of 1.60%. Given Auris Medical’s stronger consensus rating and higher possible upside, equities analysts plainly believe Auris Medical is more favorable than Audentes Therapeutics.

Profitability

This table compares Auris Medical and Audentes Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auris Medical N/A -343.01% -80.81%
Audentes Therapeutics N/A N/A -52.43%

Institutional and Insider Ownership

24.9% of Auris Medical shares are owned by institutional investors. Comparatively, 79.0% of Audentes Therapeutics shares are owned by institutional investors. 47.3% of Audentes Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Auris Medical and Audentes Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Auris Medical N/A N/A -$31.13 million ($0.67) -0.57
Audentes Therapeutics N/A N/A -$59.66 million ($3.49) -10.69

Audentes Therapeutics is trading at a lower price-to-earnings ratio than Auris Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Auris Medical beats Audentes Therapeutics on 6 of the 11 factors compared between the two stocks.

About Auris Medical

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

About Audentes Therapeutics

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply